ThermoGenesis and the Stem Cell Program at the University of California to develop stem cell therapies based upon ThermoGenesis’ AutoXpress, BioArchive and CryoSeal Fibrin Sealant blood processing systems.

Through this research collaboration at SCP, the researchers will be investigating the cell populations and fibrin gel carriers isolated from bone marrow and cord blood using our blood processing systems. The focus will be on stem cell treatments for peripheral artery disease, myocardial infarction and dermal wounds. They will provide the stem cells that the physicians need to treat these large patient population diseases.

Here internationally recognized stem cell experts Dr. Jan Nolta and Gerhard Bauer will work together.

Under the terms of the agreement, ThermoGenesis will supply SCP with an AXP Platform, one BioArchive and one CryoSeal FS System for use in their translational cell therapy research, which will focus on sourcing the stem cells from the patient’s own bone marrow or umbilical cord blood. ThermoGenesis will have first option to negotiate a license to the resulting intellectual property.

UC Davis is committed to playing a leading role in unlocking the potential of non-controversial adult stem cells and advancing these cell therapies into clinical practice as treatments for numerous life-threatening diseases.

UC Davis has more than 50 scientists working on a variety of stem cell investigations in both Davis and Sacramento. The university is currently constructing a 100,000 square foot stem cell research facility on its campus in Sacramento, where researchers will have access to state-of-the-art laboratories and cell manufacturing and testing rooms.

That project, along with the newly-funded Translational Human Embryonic Stem Cell Shared Research Facility in Davis, will complement the university’s Clinical and Translational Science Center, which is supported by the National Institutes of Health (NIH). In 2005, the NIH awarded $6 million to fund a Center of Excellence in Translational Human Stem Cell Research on the Davis campus. The California Institute for Regenerative medicine (CIRM) has awarded over $11 million to researchers at UC Davis, to develop stem cell cures.

Source: Emaxhealth